Literature DB >> 3608621

Pharmacokinetics of sulfadoxine and pyrimethamine after Fansidar administration in man.

M D Edstein.   

Abstract

The pharmacokinetics of sulfadoxine (SULF) and pyrimethamine (PYR) were studied in 7 healthy volunteers after a single oral dose of Fansidar. A comparison was made between the pharmacokinetics of the components of Fansidar calculated from whole blood and plasma data. The mean whole blood to plasma concentration ratios of SULF and PYR were 0.62 and 0.87, respectively. The elimination half-lives of SULF and PYR were similar in whole blood and plasma. The apparent volume of distribution and clearance of SULF and PYR in whole blood were significantly higher (p less than 0.01) than the corresponding plasma values. Because malaria-infected erythrocytes appear to concentrate SULF, it may be more relevant to measure drug concentrations in whole blood rather than in plasma in assessing the antimalarial efficacy of Fansidar.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3608621     DOI： 10.1159/000238499

Source DB:  PubMed          Journal:  Chemotherapy        ISSN： 0009-3157            Impact factor:   2.544


  11 in total

1.  The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

Authors:  P A Winstanley; W M Watkins; C R Newton; C Nevill; E Mberu; P A Warn; C M Waruiru; I N Mwangi; D A Warrell; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

2.  Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.

Authors:  M D Edstein; K H Rieckmann; J R Veenendaal
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

5.  Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group.

Authors:  R McLeod; D Mack; R Foss; K Boyer; S Withers; S Levin; J Hubbell
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 6.  Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.

Authors:  Philip J Peters; Michael C Thigpen; Monica E Parise; Robert D Newman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Parasitologic Assessment of Two-Dose and Monthly Intermittent Preventive Treatment of Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTP-SP) in Lagos, Nigeria.

Authors:  Chimere O Agomo; Wellington A Oyibo; Funke Odukoya-Maije
Journal:  Malar Res Treat       Date:  2011-10-26

9.  Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.

Authors:  Eva Maria Hodel; Abdunoor Mulokozi Kabanywanyi; Aggrey Malila; Boris Zanolari; Thomas Mercier; Hans-Peter Beck; Thierry Buclin; Piero Olliaro; Laurent Arthur Decosterd; Blaise Genton
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

10.  A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.

Authors:  Yiting Yang; Zexin Zhang; Ping Li; Weimin Kong; Xiaodong Liu; Li Liu
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.